Detalhe da pesquisa
1.
Trial of Intravenous Immune Globulin in Dermatomyositis.
N Engl J Med
; 387(14): 1264-1278, 2022 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36198179
2.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(9): 1130-1141, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37308218
3.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Ann Rheum Dis
; 82(1): 119-129, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36137735
4.
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin.
Rheumatol Int
; 43(9): 1629-1636, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37368037
5.
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis.
Rheumatol Int
; 43(6): 1041-1053, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36828925
6.
Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies.
Rheumatology (Oxford)
; 61(6): 2512-2523, 2022 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34698804
7.
Trial of Intravenous Immune Globulin in Dermatomyositis. Reply.
N Engl J Med
; 388(1): 94-95, 2023 01 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36599070
8.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Ann Rheum Dis
; 79(11): 1400-1413, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32759265
9.
High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies.
Rheumatology (Oxford)
; 59(11): 3515-3525, 2020 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32830270
10.
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(4): 575-577, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36720582
11.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5â years: integrated analysis of data from the global clinical trials.
Ann Rheum Dis
; 76(7): 1253-1262, 2017 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-28143815
12.
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Ann Rheum Dis
; 75(7): 1293-301, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26275429
13.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Lancet
; 381(9865): 451-60, 2013 Feb 09.
Artigo
Inglês
| MEDLINE | ID: mdl-23294500
14.
Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis.
Arthritis Rheum
; 65(11): 2765-72, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23917967
15.
Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Arthritis Rheum
; 65(6): 1430-8, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23460074
16.
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
Nat Rev Rheumatol
; 20(2): 101-115, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38216757
17.
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
RMD Open
; 10(2)2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38609322
18.
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.
Rheumatol Ther
; 11(1): 157-175, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38180720
19.
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.
Arthritis Res Ther
; 26(1): 27, 2024 01 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38233885
20.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Arthritis Rheumatol
; 2024 Mar 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38481002